Company intelligence / Profile preview

Contura

London, England, United Kingdomcontura.com ↗

Ownership: Private
Development stage: Other

Overview

Contura has developed a proprietary, non-degradable, hydrophilic injectable hydrogel platform—2.5% iPAAG—used for long-lasting symptom relief across several indications including urinary incontinence, knee osteoarthritis, facial contouring/reconstruction, and veterinary applications. Bulkamid was sold to Axonics Modulation Technologies in 2021 but is still manufactured by Contura under an exclusive supply agreement. Arthrosamid is approved for knee osteoarthritis treatment in Europe. The company’s products are supported by robust clinical data demonstrating efficacy and safety.

Therapeutic areas: NephrologyRheumatologyOther
Modalities: DeviceHydrogel-based therapyInjectable polyacrylamide hydrogel
Industry: Implantable Medical Devices

Partnerships

Johnson & Johnson/Ethicon Women’s Health subsidiaryAxonics Modulation Technologies

Beyond the preview

Go deeper on Contura.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Contura.

Explore the full profile